Product
Izokibep
Aliases
ABY-035
4 clinical trials
3 indications
Indication
UveitisIndication
Psoriatic ArthritisIndication
Hidradenitis SuppurativaClinical trial
A Phase 2 Trial of the Efficacy and Safety of the Interleukin-17A Inhibitor Izokibep (ABY-035) in the Treatment of Non-infectious Intermediate, Posterior or Pan-uveitis (LINNAEA)Status: Completed, Estimated PCD: 2022-08-25
Clinical trial
A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Non-infectious, Intermediate-, Posterior- or Pan-uveitisStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Active Psoriatic ArthritisStatus: Active (not recruiting), Estimated PCD: 2023-11-30
Clinical trial
A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Moderate to Severe Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2023-08-02